Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells

BACKGROUND: mTOR inhibition of aromatase inhibitor (AI)-resistant breast cancer is currently under evaluation in the clinic. Everolimus/RAD001 (Afinitor®) has had limited efficacy as a solo agent but is projected to become part of combination therapy for AI-resistant breast cancer. This study was co...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMC Cancer
Главные авторы: Lui, Asona, New, Jacob, Ogony, Joshua, Thomas, Sufi, Lewis-Wambi, Joan
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2016
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4947349/
https://ncbi.nlm.nih.gov/pubmed/27421652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2490-z
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы